Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) hit a new 52-week high on Monday . The stock traded as high as C$0.12 and last traded at C$0.12, with a volume of 60720 shares. The stock had previously closed at C$0.13.
Hemostemix Stock Performance
The firm has a market cap of C$12.63 million, a price-to-earnings ratio of -7.25 and a beta of 0.20. The business’s 50 day moving average price is C$0.09 and its 200-day moving average price is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- How to Invest in Small Cap Stocks
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- About the Markup Calculator
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- How to Use Stock Screeners to Find Stocks
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
